Clinical Trial Update: Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B [Phase 1]

View source ↗

Summary

Phase 1 safety study of a 40 kDa pegylated recombinant factor IX in non-bleeding patients with Haemophilia B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Bleeding Disorder
• Haemophilia

Drugs mentioned

• Pegylated recombinant factor IX (40 kDa) (pegylated recombinant factor IX)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia B | Phase 1 | Status: COMPLETED